Not Yet RecruitingNot Applicable

Reducing Co-occurring Substance Use and HIV Risk Among Stimulant-using Men at High Risk for HIV in the United States of America.

84 participantsStarted 2026-04-15

Plain-language summary

This intervention will focus on stimulant-using men at high risk for HIV who are in need of tailored behavioral interventions to mitigate co-occurring stimulant use and HIV risk in the era of pre-exposure prophylaxis (PrEP). The study is a pilot randomized controlled trial to evaluate the adaptation, feasibility, acceptability, and preliminary efficacy of a behavioral intervention.

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. be 18 years of age or older;
✓. be sexually active cisgender men at high risk for HIV (foreign and US-born, residing in the US)-reporting any condomless anal sex (CAS) in the past three months with a man;
✓. report use of stimulant (i.e., methamphetamine, powder cocaine, or crack-cocaine) at least one day in the past three or six month;
✓. have HIV-negative serostatus;
✓. be bilingual (Spanish and English), or Spanish or English monolingual;
✓. meet CDC criteria for PrEP eligibility.

Exclusion criteria

✕. display diminished capacity to consent (e.g., cognitive impairment); or
✕. severe psychiatric symptoms (e.g., psychosis) that require more intensive treatment;
✕. if they are HIV positive or living with HIV;
✕. if they are already taking PrEP; and
✕. if the participant can't consent to participate in English or Spanish.

What they're measuring

Rate of PrEP uptake

Timeframe: From enrollment to 6 months

Trial details

NCT IDNCT07281378

SponsorUniversity of Florida

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-05-31

Contact for this trial

Jose Colon-Burgos, DrPH

(352) 273-9188 jcolonburgos@phhp.ufl.edu

View on ClinicalTrials.gov More Drug Use Disorders trials